MedPage Today on MSN
CELMoD drug cuts risk of myeloma progression, death by 52% in trial
Oral mezigdomide's benefit shown in patients mostly refractory to lenalidomide and anti-CD ...
Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results